US · ASBP
Aspire Biopharma Holdings, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Estero, FL 33928
- Website
- aspirebiolabs.com
Price · as of 2024-12-31
$0.21
Market cap 4.81M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | $418.40 | ||||
| 2023 | $442.00 | ||||
| 2024 | $34.40 |
AI valuation
Our deep-learning model estimates Aspire Biopharma Holdings, Inc.'s (ASBP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $0.21
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ASBP | Aspire Biopharma Holdings… | $0.21 | 4.81M | — | — | — | — | -866.02 | -736.56 | — | -97.51 | — | -736.56 | 0.00% | — | — | -14.52% | -32.00% | -13.01% | -0.82 | 3.46 | 0.09 | 0.02 | -0.11 | -76087.00% | — | -5940.00% | -0.02% | -0.16 | -2.75% | 0.00% | 0.00% | 1.21% | -367.68 | -4282.42 | — | 295.56 |
| ANNA | AleAnna, Inc. | $2.85 | 115.88M | — | — | — | — | -18.73 | 7.79 | 163.93 | -62.29 | -9.14 | 7.79 | 17.14% | -1024.81% | -869.25% | -79.96% | -18.01% | -21.29% | 5.54 | — | 13.18 | 12.48 | -23.11 | 20486.00% | — | 17234.00% | -17.17% | -7.14 | -49.46% | 0.00% | 0.00% | 0.00% | -25.43 | -9.26 | 260.60 | 0.83 |
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
- CEO
- Kraig T. Higginson
- Employees
- 2
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $0.21) − 1 = — (DCF, example).